Loading publications…
The last 5 uploaded publications
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
David S. Hong, Ajay K. Gopal, Alexander N. Shoushtari, Sandip Pravin Patel, Aiwu Ruth He, Toshihiko Doi, Suresh S. Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B. Davis, Timothy S. Fisher, Bo Huang, Kolette D. Fly, Antoni Ribas (2022). Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. , 13, DOI: https://doi.org/10.3389/fimmu.2022.897991.
Article62 days agoA first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, Amita Patnaik, Christina Messiou, David Olmos, George Wang, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Shobha Seetharam, Johann S. de Bono, Anthony W. Tolcher (2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. , 71(4), DOI: https://doi.org/10.1007/s00280-013-2099-8.
Article62 days agoPre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.
Martin Förster, Amita Patnaik, Shahneen Sandhu, K. Papadopoulos, Brenda Tromp, Christina Messiou, Frances R. Balkwill, Birge Berns, Johann S. de Bono, A. W. Tolcher (2010). Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.. , 28(15_suppl), DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.2548.
Article62 days agoAbstract A102: First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors
Shahneen Sandhu, Peter C.C. Fong, Amita Patnaik, K. Papadopoulos, Christina Messiou, Susan Hoare, David Olmos, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Johann S. de Bono, Anthony W. Tolcher (2009). Abstract A102: First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors. , 8(12_Supplement), DOI: https://doi.org/10.1158/1535-7163.targ-09-a102.
Article62 days agoFirst-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors
Shahneen Sandhu, Peter C.C. Fong, Sophia Frentzas, Amita Patnaik, K. Papadopoulos, Brenda Tromp, Thomas A. Puchalski, Birge Berns, Anthony W. Tolcher, Johann S. de Bono (2009). First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors. , 27(15_suppl), DOI: https://doi.org/10.1200/jco.2009.27.15_suppl.e13500.
Article62 days ago